Abstract
Peroxisome proliferator-activated receptor gamma (PPARγ) activation by its ligands reportedly inhibits monocyte function. However, because the concentrations of PPARγ ligands used in previous studies were higher than typically expected to activate PPARγ, we clarified whether PPARγ ligands influence monocyte function and cell viability of the human monocyte cell line THP-1. We determined tumor necrosis factor-alpha (TNF-α) release as a monocyte function and cell viability using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide. Both troglitazone and 15-deoxy-Δ12,14-prostaglandin J2 (15-d-PGJ2) seemed to inhibit phorbol ester-induced TNF-α release from THP-1 cells. On the other hand, neither pioglitazone nor rosiglitazone inhibited phorbol ester-induced TNF-α release. Because the cytotoxicity of troglitazone and 15-d-PGJ2 was significantly (p<0.05, Tukey–Kramer) stronger than that of pioglitazone and rosiglitazone, the inhibition of TNF-α release seemed to parallel the lack of cell viability. We concluded that PPARγ ligands did not directly inhibit TNF-α release in THP-1 cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Forman BM, Tontonoz P, Chen J, Burn RP, Spiegelman BM, Evans RM. 15-Deoxy-delta12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARgamma. Cell. 1995;83;803-12.
Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA. 1997;94:4312-7.
Franzese O, Bonmassar E, Barcucci A, D'onofrion C. Functional antagonism between OL-2 and PGA1 or PGJ2 in the control of proliferation of human cord blood-derived mononuclear cells. Int J Immunopharmacol. 1996;18:609-22.
Fujiwara T, Ohsawa T, Takahashi, et al. Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats. Life Sci. 1998;63:2039-47.
Inoue I, Katayama S, Takahashi K, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun. 1997;235:113-6.
Jiang C, Ting A, Seed B. PPARgamma agonists inhibit produc-tion of monocyte inflammatory cytokines. Nature. 1998; 391:82-6.
Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130:43-52.
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Wilsom TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). J Biol Chem. 1995; 270:12953-6.
Lehmann JM, Lenahard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272: 3406-10.
Lin R, Ruuska E, Shaw NS, Dong D, Noy N. Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry. 1999;38:185-90.
Murakami K, Tobe K, Ide T et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPAR gamma. Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes. 1998;47:1841-7.
Peraldi P, Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem. 1998; 182:169-75.
Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest. 1997;100:1863-9.
Reginato MJ, Bailey ST, Krwakow SL et al. A potent antidia-betic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. J Biol Chem. 1998;273:32679-84.
Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation. Nature. 1998; 391:79-82.
Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45: 1661-9.
Szalkowski D, White-Carrington S, Berger J, Zhang B. Anti-diabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 1995;136:1474-81.
Rights and permissions
About this article
Cite this article
Naitoh, T., Kitahara, M. & Tsuruzoe, N. The effect of activation of peroxisome proliferator-activated receptor gamma (PPARγ) on human monocyte function: PPARγ ligands do not inhibit tumor necrosis factor-α release in human monocytic cell line THP-1. Cell Biol Toxicol 16, 131–135 (2000). https://doi.org/10.1023/A:1007694110835
Issue Date:
DOI: https://doi.org/10.1023/A:1007694110835